Shots:
- Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for ~$1.075B, incl. cash & a $50M seller note, as part of its portfolio optimization strategy
- The divested unit, which offers antimicrobial susceptibility testing and culture media solutions, generated $645M in revenue in 2025 and operates within Thermo Fisher’s Specialty Diagnostics segment
- The transaction is expected to close in H2’26, subject to regulatory approvals, & will allow Thermo Fisher to redeploy additional capital to create shareholder value
Ref: Businesswire | Image: Thermo Fisher & Astorg | Press Release
Related News: Thermo Fisher Scientific’s Oncomine Dx Target Test Receives US FDA Approval as a Companion Diagnostic
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
